Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Press Release
Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.
More Articles...
- EACS: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People
- ICAAC: Interferon May Reduce Liver Disease Progression in HIV/HCV Coinfected Relapsers
- ICAAC: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
- HCV Can Be Sexually Transmitted Between HIV+ Men
- Gene Variation Linked to Liver Cancer in Hepatitis C Patients
Web Design and Development by